Kadono, Y. et al. 2021. Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urology Journal. 19, 03 (Dec. 2021), 202–208. DOI:https://doi.org/10.22037/uj.v19i03.6652.